DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Information source: University of Michigan Cancer Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Graft-Versus-Host Disease

Intervention: Etanercept (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: University of Michigan Cancer Center

Official(s) and/or principal investigator(s):
John E. Levine, MS MD, Principal Investigator, Affiliation: The University of Michigan

Summary

Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved.

Clinical Details

Official title: The Use of Etanercept (Enbrel) in the Treatment of Acute Graft-Versus-Host Disease

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Primary outcome: To evaluate the response rate of etanercept when administered with steroids for treatment of biopsy proven aGVHD.

Secondary outcome: To analyze intracellular cytokine levels, lymphocyte phenotype and plasma cytokine levels in patients with aGVHD before and after treatment with etanercept and to correlate these laboratory endpoints with clinical outcomes during the trial.

Detailed description: The standard treatment for acute graft-versus-host disease is a combination of steroids and tacrolimus or cyclosporine. Previous work has shown that less than 50% of patients respond fully to GVHD. Without a good response, patients often have a prolonged treatment for this disease, often involving hospitalization and sometimes even death.

Etanercept is a drug that blocks a chemical called Tumor Necrosis Factor (TNF) from causing damage to tissue. Etanercept (Enbrel) will be added to help improve the response to standard treatment for graft-versus-host disease (GVHD).

This is an experimental research project. It is not known whether the etanercept will actually improve the body's response to graft-versus-host disease. This treatment is meant to determine if etanercept will improve your response to treatment of GVHD.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient may be transplanted with stem cells from any source using either a

myeloablative or nonmyeloablative preparative regimen

- Patient may be any age

- Patient must have biopsy proven new onset of aGVHD; Clinical Grading must be II-IV and

may occur after stem cell transplant or donor leukocyte infusion (DLI). Patients may begin Etanercept treatment prior to biopsy confirmation of GVHD. Acute GVHD will be determined by clinical presentation and not timing from stem cell infusion

- Patient must be on solumedrol at a dose of 2mg/kg/day of actual body weight for no

more than 72 hours prior to the initiation of etanercept

- Patient must have evidence of neutrophil engraftment with an ANC of > 500 for three

consecutive days

- Pulse ox > 90% on room air

Exclusion Criteria:

- Pregnancy or nursing mother

- Intolerance or allergic reaction to etanercept

- Previous use of steroids for treatment of acute GVHD

- Active infection, chronic or localized, not responding to antibiotics, with continued

signs of infection (patients with a positive C. Difficile test will not be excluded from the study)

- Condition that might predispose to developing serious infections (i. e. active and

uncontrolled diabetes mellitus, sickle cell anemia)

- Other investigational agents for the treatment or prophylaxis of graft-vs-host disease

within the past 2 weeks

- Serum creatinine > 2. 0mg/dl

- Patients being treated for acute pulmonary dysfunction (IPS) study using etanercept

- Patients with hypotension believed to be secondary to sepsis syndrome or heart failure

requiring > 1 inotropic agent, or dopamine >5mcg/kg/minute for blood pressure support

- Evidence of congestive heart failure on clinical exam

- Evidence of hepatic dysfunction with an ALT or AST > 2. 5 x ULN, not due to GVHD

Locations and Contacts

The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, United States
Additional Information

Starting date: October 2003
Ending date: September 2012
Last updated: January 31, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014